July 19 (Reuters) - Progenics Pharmaceuticals Inc PGNX.O :
* Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016
* Valeant and Progenics announce FDA approves relistor tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain
* FDA has approved relistor (methylnaltrexone bromide) tablets for treatment of opioid-induced constipation Source text for Eikon: ID:nCNWDRJsda Further company coverage: PGNX.O
(Bengaluru Newsroom: +1-646-223-8780)